MedTrace Logo

Comparative Effectiveness of System Interventions to Increase HPV Vaccine Receipt in FQHCs

NCT03726151 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17000

Last updated 2026-05-12

No results posted yet for this study

Summary

UCLA and Northeast Valley Health Center (NEVHC), a large, multi-site Federally Qualified Health Center (FQHC), are partnering to address underutilization of the prophylactic HPV vaccine among underserved, ethnic minority adolescents receiving care through FQHCs. We will use a cluster randomized 2x2 stepped-wedge factorial study design, implemented in seven NEVHC clinics, to compare the effectiveness of parent reminders (mailed and text), multi-component clinic system strategies, a combined intervention (parent reminders + clinic system strategies) and usual care on HPV vaccine series completion among NEVHC adolescent patients. FQHCs provide essential health care to underserved groups and have the infrastructure to sustain effective strategies to improve preventive care delivery. Therefore, study findings will be invaluable for informing future efforts to improve HPV vaccination at the population-level.

Conditions

  • Human Papillomavirus Infection

Interventions

BEHAVIORAL

Parent Reminders

Automated, system-generated mailed or text message reminders

BEHAVIORAL

Multicomponent clinic-system strategies

1. Workflow modifications to reduce missed opportunities for vaccination 2. Provider- and clinic-level audit and feedback 3. Provider \& staff training on workflow modifications and communication strategies

BEHAVIORAL

Combined Condition

Parent reminders and multicomponent clinic-system strategies

Sponsors & Collaborators

Principal Investigators

  • Roshan Bastani, PhD · Professor, Health Policy and Management, UCLA Fielding School of Public Health

  • Beth Glenn, PhD · Professor, Health Policy and Management, UCLA Fielding School of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
11 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2024-03-28
Completion
2024-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03726151 on ClinicalTrials.gov